With a market capitalization (market cap) of $1.84B — a measure of how much the company is worth — Lakefront Biotherapeutics N.V. is the 2167th most valuable company in Healthcare as of August 18, 2026. Shares trade at $27.99, up +1.71% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Visit websiteAs of August 18, 2026, Lakefront Biotherapeutics N.V. (LKFT) is worth $1.84B — this is its market capitalization, the total value of all its outstanding shares.
Lakefront Biotherapeutics N.V.’s market cap is $1.84B, which ranks it #2167 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Lakefront Biotherapeutics N.V. (LKFT) shares trade at $27.99, up 1.71% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Lakefront Biotherapeutics N.V. trades at a price-to-earnings (P/E) ratio of 5.7, based on its latest share price and annual earnings per share.